Sanegene Bio USA Inc
- | Biotech or pharma, therapeutic R&D
Sanegene Bio is a Boston-based clinical-stage emerging RNAi-focused biotechnology company dedicated to developing innovative RNA interference (RNAi) therapeutics through cutting-edge delivery technologies. Founded in 2021, Sanegene Bio is powered by a team of industry-leading experts and operates in both the United States and China.
Our pipeline includes:
- Three clinical-stage siRNA assets, targeting cardiovascular and metabolic diseases (e.g., PCSK9 and AGT) and immune diseases (e.g., Complement C3).
- Two IND-stage assets and several others in preclinical development.
For extrahepatic targets, we have developed the proprietary LEAD (Ligand- and Enhancer-Assisted Delivery) platform. This platform enables siRNA delivery to various extrahepatic tissues, including Muscle, Adipose, CNS/PNS, Macrophages, Ocular etc.
Address
BostonUnited States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}